Table 2. The suppressive effects of zacopride therapeutic treatment on acute ischemic arrhythmias in anesthetized rats in vivo (mean ± SEM).

	n	Latency time of the first susVT/VF (s)	Termination time of the first susVT/VF (s)	The remaining episodes of PVC	Total duration of the remaining VT (s)	Total duration of the remaining VF (s)
Control	8	428.9±30.3#	129.8±54.5	110±21	191.4±55.5	30.1±11.0
Zac 15 μg/kg	8	465.1±53.3	27.5 ±5.5*	26±10**	51.9±10.9**	0**
Lidoc 7.5 mg/kg	8	494.1±44.0#	26.5±7.3*#	20±5**#	40.4±11.8**#	0.5±0.3**#

Latency time of the first susVT/VF, the time from coronary occlusion to the onset of the first sustained VT or VF. Sustained VT or VF was designated a sustained time > 30 s. Termination time of the first susVT/VF, the time from drug administration to the termination of the first sustained VT or VF. Total duration of the remaining VT/VF (s), total duration (s) of the remaining VT/VF during the period from the termination of the first sustained VT/VF to the 15th min after coronary occlusion.

* P < 0.05,

** P < 0.01 vs. control,

^# P > 0.05 vs.15 μg/kg Zac.